Somewhat Positive News Coverage Somewhat Unlikely to Affect Chemours Company (The) (CC) Share Price
Media headlines about Chemours Company (The) (NYSE:CC) have trended somewhat positive on Friday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chemours Company (The) earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the specialty chemicals company an impact score of 46.1153258477749 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Chemours Company (The) (CC) SVP Sells $1,019,920.00 in Stock (americanbankingnews.com)
- Chemours Announces Dates for Third Quarter 2017 Earnings Release and Webcast Conference Call (finance.yahoo.com)
- Opteon™ 1100 Wins 2017 Polyurethane Innovation Award – PR Newswire (press release) (prnewswire.com)
- Stock in Buy Zone: The Chemours Company (CC) – Street Observer (press release) (streetobserver.com)
Several research analysts recently weighed in on CC shares. Zacks Investment Research upgraded shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 price objective on the stock in a research report on Friday, July 14th. BidaskClub cut shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $48.00 target price on shares of Chemours Company (The) in a research note on Friday, June 16th. Citigroup Inc. upped their target price on Chemours Company (The) from $45.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Finally, J P Morgan Chase & Co upped their target price on Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Chemours Company (The) has a consensus rating of “Buy” and a consensus price target of $52.75.
Shares of Chemours Company (CC) opened at 54.43 on Friday. The firm has a 50-day moving average price of $51.28 and a 200 day moving average price of $51.28. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of 35.62 and a beta of 3.59. Chemours Company has a 52 week low of $14.41 and a 52 week high of $54.47.
Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the company posted $0.27 EPS. The company’s revenue was up 14.8% compared to the same quarter last year. On average, analysts forecast that Chemours Company will post $3.51 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.22%. The ex-dividend date of this dividend was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is currently 8.11%.
In other news, VP Amy Trojanowski sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David C. Shelton sold 19,000 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $53.68, for a total value of $1,019,920.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,837 shares of company stock worth $2,885,523. Corporate insiders own 1.14% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Chemours Company (The) (CC) Share Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-chemours-company-the-cc-share-price.html.
About Chemours Company (The)
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.